These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 31256939)

  • 1. Real-world use of telavancin in the treatment of osteomyelitis.
    Saravolatz LD; Cleveland KO; Rikabi K; Hassoun A; Reilly J; Johnson LB; Spak C; Valenti S; Szpunar S
    Diagn Microbiol Infect Dis; 2019 Oct; 95(2):185-190. PubMed ID: 31256939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study.
    Stryjewski ME; Lentnek A; O'Riordan W; Pullman J; Tambyah PA; Miró JM; Fowler VG; Barriere SL; Kitt MM; Corey GR
    BMC Infect Dis; 2014 May; 14():289. PubMed ID: 24884578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telavancin for the treatment of methicillin-resistant Staphylococcus aureus bone and joint infections.
    Harting J; Fernandez F; Kelley R; Wiemken T; Peyrani P; Ramirez J
    Diagn Microbiol Infect Dis; 2017 Dec; 89(4):294-299. PubMed ID: 29137718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outpatient treatment of osteomyelitis with telavancin.
    Schroeder CP; Van Anglen LJ; Dretler RH; Adams JS; Prokesch RC; Luu Q; Krinsky AH
    Int J Antimicrob Agents; 2017 Jul; 50(1):93-96. PubMed ID: 28456704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telavancin for refractory MRSA bacteraemia in intermittent haemodialysis recipients.
    Britt NS; Tirmizi S; Ritchie DJ; Topal JE; McManus D; Nizet V; Casabar E; Sakoulas G
    J Antimicrob Chemother; 2018 Mar; 73(3):764-767. PubMed ID: 29244141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telavancin for the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis.
    Twilla JD; Gelfand MS; Cleveland KO; Usery JB
    J Antimicrob Chemother; 2011 Nov; 66(11):2675-7. PubMed ID: 21831987
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful treatment of polymicrobial calcaneal osteomyelitis with telavancin, rifampin, and meropenem.
    Brinkman MB; Fan K; Shiveley RL; Van Anglen LJ
    Ann Pharmacother; 2012 Jun; 46(6):e15. PubMed ID: 22619476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: studies with a rabbit model.
    Yin LY; Calhoun JH; Thomas TS; Wirtz ED
    J Antimicrob Chemother; 2009 Feb; 63(2):357-60. PubMed ID: 19060292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time Course and Extent of Renal Function Changes in Patients Receiving Treatment for Staphylococcal Pneumonias: An Analysis Comparing Telavancin and Vancomycin from the ATTAIN Trials.
    Nogid B; Lacy MK; Jacobs M; Bruss J; Dwyer J
    Pharmacotherapy; 2018 Oct; 38(10):990-998. PubMed ID: 30003567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus.
    Corey GR; Rubinstein E; Stryjewski ME; Bassetti M; Barriere SL
    Clin Infect Dis; 2015 Mar; 60(5):787-96. PubMed ID: 25472944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of telavancin in adolescent patients with cystic fibrosis and prior intolerance to vancomycin: A case series.
    Bernstein AT; Leigh MW; Goralski JL; Esther CR; McKinzie CJ
    J Cyst Fibros; 2018 Nov; 17(6):e48-e50. PubMed ID: 30170755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of telavancin in the treatment of MRSA infections in hospital.
    Bassetti M; Mikulska M; Righi E; Nicolini L; Viscoli C
    Expert Opin Investig Drugs; 2009 Apr; 18(4):521-9. PubMed ID: 19335280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.
    Madrigal AG; Basuino L; Chambers HF
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3163-5. PubMed ID: 16048918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective Antimicrobial Stewardship Strategies for Cost-effective Utilization of Telavancin for the Treatment of Patients With Hospital-acquired Bacterial Pneumonia Caused by Staphylococcus aureus.
    McKinnell JA; Corman S; Patel D; Leung GH; Gordon LM; Lodise TP
    Clin Ther; 2018 Mar; 40(3):406-414.e2. PubMed ID: 29454592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telavancin-associated acute kidney injury
.
    Cavanaugh C; Moeckel GW; Perazella MA
    Clin Nephrol; 2019 Mar; 91(3):187-191. PubMed ID: 30614441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of telavancin activity in in vitro biofilms and animal models of biofilm-associated infections.
    Chan C; Hardin TC; Smart JI
    Future Microbiol; 2015; 10(8):1325-38. PubMed ID: 26083676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telavancin.
    Corey GR; Stryjewski ME; Weyenberg W; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2009 Dec; 8(12):929-30. PubMed ID: 19949399
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetics of Telavancin in Adult Patients with Cystic Fibrosis during Acute Pulmonary Exacerbation.
    Kidd JM; Sakon CM; Oleksiuk LM; Cies JJ; Pettit RS; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31685468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telavancin.
    Lyseng-Williamson KA; Blick SK
    Drugs; 2009; 69(18):2607-20. PubMed ID: 19943710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telavancin: a novel lipoglycopeptide for serious gram-positive infections.
    Laohavaleeson S; Kuti JL; Nicolau DP
    Expert Opin Investig Drugs; 2007 Mar; 16(3):347-57. PubMed ID: 17302529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.